Steven Gillis - Shire Plc Non-Executive Independent Director

Director

Dr. Steven H. Gillis, Ph.D. is NonExecutive Independent Director of Shire plc., since October 1, 2012. Steven brings to the Board his extensive technical and scientific knowledge and commercial experience. He is currently a Managing Director at ARCH Venture Partners a provider of VC for technology firms. Prior to this Steven was a founder and Director of Corixa Corporationrationration, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporationrationration. An immunologist by training, Steven has authored more than 300 peerreviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine,, Prokine and Enbrel as well as the regulatory approval of Bexxar and the novel vaccine adjuvant, MPL. Steven received his BA from Williams College and his PhD from Dartmouth College. Key appointments are ARCH Venture Partners, Pulmatrix, Inc., PhaseRx Inc. and VBI Vaccines Inc. . since 2012.
Age 63
Tenure 12 years
Phone(353) 1 609 6000
Webwww.shire.com
Gillis received his BA from Williams College and his Ph.D. from Dartmouth College.

Steven Gillis Latest Insider Activity

Tracking and analyzing the buying and selling activities of Steven Gillis against Shire Plc stock is an integral part of due diligence when investing in Shire Plc. Steven Gillis insider activity provides valuable insight into whether Shire Plc is net buyers or sellers over its current business cycle. Note, Shire Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Shire Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Shire Plc Management Efficiency

Shire Plc's management efficiency ratios could be used to measure how well Shire Plc manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 15.35 B in liabilities with Debt to Equity (D/E) ratio of 41.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Shire Plc has a current ratio of 0.9, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Shire Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Shire Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Shire Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Shire to invest in growth at high rates of return. When we think about Shire Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Pamela RollinsMarine Products
63
Harry CynkusMarine Products
70
Robyn DenholmTesla Inc
54
Joachim FaberCoty Inc
67
Christopher MapesTimken Company
59
Linda GrahamMarine Products
78
Larry EllisonTesla Inc
N/A
Lawrence EllisonTesla Inc
73
Paul MichaelsCoty Inc
64
Timothy RollinsMarine Products
58
James WilliamsMarine Products
85
Bradley BussTesla Inc
54
Mariasun LarreguiCoty Inc
57
john LukeTimken Company
72
Linda RiceTesla Inc
60
Ajita RajendraTimken Company
69
Scott SorensenWabash National
59
Robert SingerCoty Inc
68
Antonio GraciasTesla Inc
47
Joseph RalstonTimken Company
73
Jack StahlCoty Inc
61
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company was founded in 1986 and is headquartered in Dublin, Ireland. Shire plc operates under Biotechnology classification in USA and is traded on NASDAQ. It employs 23044 people. Shire Plc (SHPG) is traded on NASDAQ Exchange in USA and employs 23,044 people.

Management Performance

Shire Plc Leadership Team

Elected by the shareholders, the Shire Plc's board of directors comprises two types of representatives: Shire Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shire. The board's role is to monitor Shire Plc's management team and ensure that shareholders' interests are well served. Shire Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shire Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sara Mathew, Non-Executive Director
Perry Sternberg, Head - U.S. Commercial
Ian Clark, Non-Executive Director
Christoph Brackmann, Interim Head of Investor Relations
William Mordan, General Counsel and Corporate Secretary
Gisele Dion, Chief Accounting Officer, Corporate Controller
Flemming Ornskov, CEO, Director
Bill Mordan, General Counsel, Company Secretary
Gail Fosler, Non-Executive Director
Philip Vickers, Head - Research and Development
David Ginsburg, Non-Executive Independent Director
Joanne Cordeiro, Chief Human Resource Officer
Jeffrey Poulton, CFO and Director
Matthew Walker, Head - Technical Operations
Ian Karp, Head of Investor Relations
Olivier Bohuon, Non-Executive Director
Susan Kilsby, Non-Executive Chairman of the Board
John Miller, Interim CFO
Andreas Busch, Executive Vice President - Head of Research and Development, Chief Scientific Officer
Howard Mayer, Senior Vice President -Head of Research and Development
Phil Vickers, Head of Research and Development
Albert Stroucken, Non-Executive Director
William Burns, Non-Executive Independent Director
Dominic Blakemore, Non-Executive Director
Oliver Strawbridge, Senior Assistant Company Secretary
Ginger Gregory, Chief Human Resource Officer
Steven Gillis, Non-Executive Independent Director
Kim Stratton, Head - International Commercial
David Kappler, Senior Independent Non-Executive Deputy Chairman of the Board
Thomas Dittrich, CFO, Executive Director
Anne Minto, Non-Executive Independent Director
Mark Enyedy, Head of Corporate Devel. and Interim General Counsel

Shire Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Shire Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Shire Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Shire Plc's short interest history, or implied volatility extrapolated from Shire Plc options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in Shire Stock

If you are still planning to invest in Shire Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shire Plc's history and understand the potential risks before investing.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Money Managers
Screen money managers from public funds and ETFs managed around the world
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories